Tech Company Financing Transactions
858 Therapeutics Funding Round
On 9/23/2021, 858 Therapeutics announced $60 million in Series A funding from Versant Ventures, Cormorant Asset Management and Logos Capital.
Transaction Overview
Company Name
Announced On
9/23/2021
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies and to expand its team to about 40 people within the next 18 months.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4757 Nexus Center Dr. 150
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response. 858 was founded by a veteran team who together bring a track record of success in pharma and biotech drug discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Stafford
Chief Scientific Officer
James Veal
Vice President
Gretchen Bain
Browse more venture capital transactions:
Prev: 9/23/2021: Fauna Bio venture capital transaction
Next: 9/23/2021: EarthOptics venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs